Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Whitehawk Therapeutics (WHWK) over the last 4 years, with Dec 2024 value amounting to -$2.36.

  • Whitehawk Therapeutics' EPS (Weighted Average and Diluted) rose 43.48% to -$0.26 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.13, marking a year-over-year increase of 105.70%. This contributed to the annual value of -$2.36 for FY2024, which is 3.28% up from last year.
  • Per Whitehawk Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$2.36 for FY2024, which was up 3.28% from -$2.44 recorded in FY2023.
  • Whitehawk Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$2.36 during FY2024, with a 5-year trough of -$12.41 in FY2021.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$2.44 (2023), whereas its average is -$2.50.
  • Data for Whitehawk Therapeutics' EPS (Weighted Average and Diluted) shows a peak YoY spiked of 78.32% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows Whitehawk Therapeutics' EPS (Weighted Average and Diluted) stood at -$12.41 in 2021, then soared by 78.32% to -$2.69 in 2022, then rose by 9.29% to -$2.44 in 2023, then increased by 3.28% to -$2.36 in 2024.